Patient disposition
| Subjects | 860 | |
| Total in previous controlled study | 423 (49) | |
| Randomised to receive treprostinil in previous study | 205 | |
| Randomised to receive placebo in previous study | 218 | |
| De novo patients | 437 (51) | |
| Completed# | 331 (38) | |
| Prematurely discontinued | 506 (59) | |
| Ongoing as of December 1, 2003 | 23 (3) | |
| Reason for premature discontinuation | ||
| Death | 136 (16; 27) | |
| Transplantation | 11 (1; 2) | |
| Clinical deterioration/rescue therapy | 117 (14; 23) | |
| Withdrew consent | 29 (3; 6) | |
| Adverse event | 199 (23; 39) | |
| Protocol violation | 10 (1; 2) | |
| Lost to follow-up | 4 (<1; 1) | |
Data are presented as n, n (%) or n (% total; % discontinuations). #: transitioned to commercial drug.